Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of HS-20094 injection in subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise alone. The primary objective of this study is to evaluate the effectiveness of HS-20094 compared to placebo in controlling blood glucose levels after 44 weeks and 52 weeks treatment.
Official title: A Multicenter, Randomized, Double-Blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HS-20094 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
204
Start Date
2025-09-30
Completion Date
2027-05-30
Last Updated
2025-09-05
Healthy Volunteers
No
Conditions
Interventions
HS-20094 Injection
HS-20094 injected subcutaneously once weekly
HS-20094 Placebo Injection
HS-20094 Placebo injected subcutaneously once weekly
HS-20094 Injection
HS-20094 injected subcutaneously once weekly
HS-20094 Placebo Injection
HS-20094 Placebo injected subcutaneously once weekly
Locations (1)
Beijing Hospital
Beijing, Beijing Municipality, China